Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2024 SABCS
Thematic Newsreels
2024 ASH Annual Meeting
RSNA 2024 Annual Meeting
2024 JADPRO Live
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Advertisement
Dec
30
Today In Oncology
Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle Cell Lymphoma
FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer
SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
View More
Advertisement
